Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity
Study Overview
This study explores how blood-based biomarkers (BBMs) relate to cognitive health in older adults with type 2 diabetes (T2D) and obesity. These biomarkers can help diagnose Alzheimer’s disease (AD) and related dementias (ADRD).
Study Goals
The main aim was to look at how initial BBM levels and their changes over time affect cognition in people with T2D and obesity.
Study Design
The research was part of the Look AHEAD study, which involved older adults with T2D and obesity. Participants were randomly assigned to either a weight loss program or a diabetes support program. The study took place at multiple sites across the US, starting from 2001 to 2004, with follow-ups for up to 12 years.
Key Findings
- Participants’ average age was 61.5 years, with a majority being female.
- Higher levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were linked to cognitive decline.
- Other biomarkers like Aβ42/40 ratio and phosphorylated tau 181 (pTau-181) did not show a significant association with cognitive changes.
Practical Implications
The results indicate that monitoring NfL and GFAP levels in blood could be valuable for detecting cognitive decline in patients with T2D and obesity. This may help in early intervention strategies.
Enhancing Clinical Practices
Clinical trials are essential for developing effective treatments. Our AI-driven platform, DocSym, integrates key medical standards and research, making it easier for clinicians to access vital information.
Improving Patient Care
Our mobile applications simplify scheduling, treatment monitoring, and telemedicine, enhancing overall patient management and care delivery.
AI Benefits
By leveraging AI, clinics can streamline their operations, improve patient outcomes, and reduce reliance on paper processes. Discover more at aidevmd.com.